Jun 4, 2004
Physician-scientists at NewYork-Presbyterian Hospital at the campuses of NewYork-Presbyterian/Columbia and NewYork-Presbyterian/Weill Cornell are presenting a number of papers and poster sessions at the American Society of Clinical Oncology's (ASCO) 40th Annual Meeting in New Orleans on June 5-8.
A partial list follows:
Dr. Hearn Cho will present a poster, showing that CT7 (MAGE-C1) is a widely expressed Cancer-Testis antigen in multiple myeloma. Dr. Cho is Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
Dr. Kara M. Kelly will present a talk entitled Integrating Complementary and Alternative Medicine Therapies in the Care of Children With Cancer: Research and Clinical Practice. The presentation will summarize current research on complementary and alternative medicine for children with cancer, including a recent research finding that St. John's Wort may lead to a reduction in levels of certain chemotherapy drugs. Dr. Kelly is Assistant Professor of Pediatrics at Columbia University College of Physicians Surgeons and Assistant Attending Pediatrician at Children's Hospital of NewYork-Presbyterian.
Dr. Roger Keresztes is part of a group presenting an abstract entitled Phase II Randomized Trial of Irinotecan/Docetaxel (ID) or Irinotecan/Gemcitabine (IG) With or Without Celecoxib (CBX) in Second-Line Treatment of Non-Small-Cell Lung Cancer. Dr. Keresztes is Assistant Professor of Clinical Medicine at Weill Cornell Medical College and Assistant Attending Physician at NewYork-Presbyterian/Weill Cornell.
Dr. John Leonard will present a poster, Combination of CpG7909 and Rituximab in Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL): A Phase I, Open Label Dose-Escalation Study of Safety and Tolerability. The study attempts to treat Lymphoma without the use of chemotherapy. Dr. Leonard is Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at NewYork-Presbyterian/Weill Cornell.
Dr. James McKiernan has authored a paper showing that bone complications associated with prostate cancer cause a substantial economic burden. Dr. McKiernan is Assistant Professor of Urology at Columbia University College of Physicians Surgeons and Assistant Attending Urologist at NewYork-Presbyterian Hospital/Columbia University Medical Center.
Dr. Daniel Petrylak has authored a paper demonstrating that men with androgen-independent metastatic prostate cancer treated with the breast-cancer drug Taxotere in combination with the drug estramustine survived 20 percent longer than similar patients receiving the standard therapy. Dr. Petrylak is Associate Professor of Medicine at Columbia University College of Physicians Surgeons and Director of the Genitourinary Oncology Program at New York-Presbyterian/Columbia.
Dr. Harry Raftopoulos will present findings from a Phase II multi-center study of the drug indisulam in kidney cancer patients who have failed previous options as well as a meta-analysis of studies to assess which is the best platinum drug to use in lung cancer. Dr. Raftopoulos is Assistant Professor of Medicine at Columbia University College of Physicians Surgeons and Assistant Attending Physician at NewYork-Presbyterian/ Columbia.
Dr. Tsiporah Shore will present a poster entitled A Study of a Non-myeloablative Conditioning Regimen Followed by Allogeneic Stem Cell Transplant for Patients with Hematological Malignancies, Using Campath as Part of Graft-versus-Host Disease Strategy. Dr. Shore is Assistant Professor of Clinical Medicine at Weill Cornell Medical College and Assistant Attending Physician at NewYork-Presbyterian/Weill Cornell.
Dr. Scott Wadler is presenting data from an analysis of early lung lesions, including a mini-transplant approach to stem-cell transplants for patients with leukemia, which uses just enough chemo to suppress the immune system so patients won't reject donor cells. It is a milder, yet effective, approach that can be given to patients who would never have been able to survive a more toxic transplant. Dr. Wadler is the Richard T. Silver Distinguished Professor of Hematology and Oncology at Weill Cornell Medical College and Attending Physician at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.